Published in Am J Public Health on October 01, 1985
Policy issues related to prospective payment for pediatric hospitalization. Health Care Financ Rev (1987) 0.92
Trauma case mix and hospital payment: the potential for refining DRGs. Health Serv Res (1991) 0.79
High cost factors for leukaemia and lymphoma patients: a new analysis of costs within these diagnosis related groups. J Epidemiol Community Health (1999) 0.75
Measuring severity of illness: comparisons across institutions. Am J Public Health (1983) 2.49
Measuring severity of illness: homogeneous case mix groups. Med Care (1983) 1.99
The Severity of Illness Index as a severity adjustment to diagnosis-related groups. Health Care Financ Rev (1984) 1.84
Three case-type classifications: suitability for use in reimbursing hospitals. Med Care (1982) 1.32
Does severity of illness make a difference in prospective payment? Healthc Financ Manage (1983) 1.32
An empiric study of ecological inference. Am J Public Health (1984) 0.96
The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med (1992) 6.05
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. AJNR Am J Neuroradiol (1995) 2.80
Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet (1998) 2.75
Preventing adverse drug events in hospitalized patients. Ann Pharmacother (1994) 2.74
Effect of practice variation on resource utilization in infants hospitalized for viral lower respiratory illness. Pediatrics (2001) 2.72
Results of a collaborative quality improvement program on outcomes and costs in a tertiary critical care unit. Crit Care Med (1999) 2.72
International comparison of waiting times for selected cardiovascular procedures. J Am Coll Cardiol (1995) 2.71
Role of osteopontin in tumour progression. Br J Cancer (2004) 2.65
Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res (2000) 2.58
Measuring severity of illness: comparisons across institutions. Am J Public Health (1983) 2.49
Interhospital differences in severity of illness. Problems for prospective payment based on diagnosis-related groups (DRGs). N Engl J Med (1985) 2.00
Measuring severity of illness: homogeneous case mix groups. Med Care (1983) 1.99
The relationship between severity of illness and hospital length of stay and mortality. Med Care (1991) 1.91
A survey to evaluate parental consent as public policy for neonatal screening. Am J Public Health (1982) 1.89
Continuity and coordination in primary care: their achievement and utility. Med Care (1976) 1.85
The Severity of Illness Index as a severity adjustment to diagnosis-related groups. Health Care Financ Rev (1984) 1.84
CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res (1999) 1.82
A study of the relationship between severity of illness and hospital cost in New Jersey hospitals. Health Serv Res (1992) 1.78
Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin Exp Metastasis (1993) 1.73
Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res (1997) 1.71
Continuity of care: is it cost effective? Am J Manag Care (1999) 1.71
Measuring severity of illness to predict patient resource use within DRGs. Inquiry (1983) 1.65
Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer (1998) 1.64
Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis (1994) 1.64
Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci (1999) 1.63
Psychiatric severity of illness. A case mix study. Med Care (1989) 1.62
Validity, reliability and implications of an index of inpatient severity of illness. Med Care (1981) 1.59
Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res (1995) 1.52
Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene (1999) 1.51
Information factors affecting problem follow-up in ambulatory care. Med Care (1976) 1.51
Severity assessment in children hospitalized with bronchiolitis using the pediatric component of the Comprehensive Severity Index. Pediatr Crit Care Med (2000) 1.49
An analysis of case mix complexity using information theory and diagnostic related grouping. Med Care (1979) 1.47
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene (2006) 1.47
Do ophthalmologists, anesthesiologists, and internists agree about preoperative testing in healthy patients undergoing cataract surgery? Arch Ophthalmol (1995) 1.45
The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med (2001) 1.45
The content and cost of cataract surgery. Arch Ophthalmol (1993) 1.44
Measuring severity: how sick is sick? How well is well? Healthc Financ Manage (1986) 1.41
Pathophysiologic determinants of third heart sounds: a prospective clinical and Doppler echocardiographic study. Am J Med (2001) 1.41
Postoperative management of cataract surgery patients by ophthalmologists and optometrists. Arch Ophthalmol (1996) 1.39
Does severity of illness make a difference in prospective payment? Healthc Financ Manage (1983) 1.32
Variations in utilization of health services by children. Pediatrics (1979) 1.32
Hospital case mix groupings and generic algorithms. QRB Qual Rev Bull (1982) 1.30
Severity of illness within DRGs. Homogeneity study. Med Care (1986) 1.30
Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol (2001) 1.30
Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer (1996) 1.30
Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res (1994) 1.30
Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis (1993) 1.27
Ambulatory severity index: development of an ambulatory case mix system. J Ambul Care Manage (1988) 1.27
Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci U S A (1996) 1.25
The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia (2001) 1.24
Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem (2000) 1.24
Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab (2001) 1.23
Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res (1994) 1.23
Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun (1988) 1.22
Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett (1997) 1.21
Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer (1990) 1.18
Measuring severity of illness: a reliability study. Med Care (1983) 1.16
Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids (1995) 1.16
p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst (1994) 1.13
Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem (2000) 1.12
The Computerized Psychiatric Severity Index as a predictor of inpatient length of stay for psychoses. Med Care (1991) 1.11
Comparing classification methods: measurement of variations in charges, length of stay, and mortality. Med Care (1982) 1.09
Goodness-of-fit tests for discrete data: a review and an application to a health impairment scale. Biometrics (1977) 1.08
Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res (1995) 1.08
Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med (1997) 1.07
High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest (1985) 1.05
A model system for studying metastasis using the embryonic chick. Cancer Res (1982) 1.04
Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat (2001) 1.04
Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem (1996) 1.04
Validity of medical staff judgments in establishing quality assurance priorities. Med Care (1979) 1.04
Priority setting in quality assurance: reliability of staff judgments in medical institutions. Med Care (1978) 1.03
Experimental metastatic ability of H-ras-transformed NIH3T3 cells. Cancer Res (1985) 1.02
Human isopentenyl diphosphate: dimethylallyl diphosphate isomerase: overproduction, purification, and characterization. Arch Biochem Biophys (1996) 1.02
Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science (1984) 1.01
Physicians and non-physician health practitioners: the characteristics of their practices and their relationships. Am J Public Health (1978) 1.00
Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem (1994) 0.99
Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc Natl Acad Sci U S A (1982) 0.99
Early and sufficient feeding reduces length of stay and charges in surgical patients. J Surg Res (2001) 0.99
Clonal heterogeneity, experimental metastatic ability, and p21 expression in H-ras-transformed NIH 3T3 cells. J Natl Cancer Inst (1988) 0.97
Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem (1995) 0.97
Severity of illness and resource use differences among white and black hospitalized elderly. Arch Intern Med (1992) 0.97
Formulary limitations and the elderly: results from the Managed Care Outcomes Project. Am J Manag Care (1998) 0.97